Shilpa Medicare gains on entering into strategic partnership with NXI Therapeutics AG
Shilpa Medicare is currently trading at Rs. 329.00, up by 5.70 points or 1.76% from its previous closing of Rs. 323.30 on the BSE.
The scrip opened at Rs. 321.00 and has touched a high and low of Rs. 332.00 and Rs. 315.60 respectively. So far 6330 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 501.60 on 16-Jun-2025 and a 52 week low of Rs. 260.00 on 27-Jan-2026.
Last one week high and low of the scrip stood at Rs. 359.95 and Rs. 315.60 respectively. The current market cap of the company is Rs. 6394.55 crore.
The promoters holding in the company stood at 40.13%, while Institutions and Non-Institutions held 19.30% and 40.56% respectively.
Shilpa Medicare has entered into strategic partnership for a long-term development and commercial manufacturing agreement with NXI Therapeutics AG, Switzerland for a novel therapy targeting autoimmune and alloimmune disorders. Under the terms of agreement, Shilpa group will provide comprehensive CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support. The collaboration spans early development through commercialization, positioning Shilpa as a lifecycle partner for the program.
The autoimmune and immune-modulation segment represents one of the fastest-growing therapeutic categories globally, driven by increasing prevalence and demand for targeted immunotherapies. By securing this mandate at an early stage, Shilpa enhances its participation in high-value, innovation-driven pipelines with scalable commercial potential.
This partnership marks the third significant international development and manufacturing contract secured by Shilpa group, underscoring strengthening demand from Western biotech companies for its integrated R&D capabilities and advanced GMP manufacturing infrastructure. While financial terms remain confidential, the agreement includes milestone-linked expansion potential and may evolve into a multi-year commercial supply relationship, subject to successful clinical and regulatory progression.
